ClinicalTrials.gg
Not yet recruitingNCT07853248Updated Oct 1, 2026

Tegoprazan-Aspirin Drug Interaction in Healthy Adult Male Volunteers

A Phase 1 interventional study of Aspirin and Tegoprazan in Healthy Adult Male, sponsored by HK inno.N Corporation. Not yet recruiting at 1 site in South Korea. Open to male participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by HK inno.N Corporation · Phase 1, Interventional, and Treatment

Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
19 Years to 50 Years
Sex
Male
01

Study summary

This Clinical Trial Aims to Evaluate the PK/PD Drug-Drug Interaction and Safety/Tolerability of Tegoprazan and Aspirin in Healthy Adult Male Volunteers.

Read the detailed description

Trial Objective

  1. Primary Objective

    • To evaluate the effect of Tegoprazan on the PK and PD of Aspirin following coadministration of Tegoprazan and Aspirin in healthy male adult participants.
    • To evaluate the effect of Aspirin on the PK of Tegoprazan following coadministration of Tegoprazan and Aspirin in healthy male adult participants.
  2. Secondary Objective

    • To evaluate the safety and tolerability of Tegoprazan and Aspirin when coadministered in healthy male adult participants.
  3. Exploratory Objective

    • To perform an exploratory evaluation of the concentrations and interconversion characteristics of isomers(R-form and S-form) in blood to explore the in vivo biotransformation profile of Tegoprazan and its metabolites in healthy male adult participants.
02

Conditions studied

  • Healthy Adult Male
03

In context

Lead sponsor

HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male adult volunteers aged ≥19 years and ≤50 years at the time of screening
  2. Participants who weigh ≥50.0 kg and ≤90.0 kg at the time of screening and have a (BMI, Body Mass Index) of ≥18.5 kg/m² and ≤29.9 kg/m²
  3. Participants who, after receiving a sufficient explanation of and fully understanding this clinical trial, voluntarily decide to participate and provide written consent to comply with the precautions
  4. Participants who are determined to be negative in the Helicobacter pylori Antibody test
  5. Participants considered eligible for participation in this clinical trial by the investigator based on physical examination, clinical laboratory tests, medical interview, etc.

Exclusion criteria

Exclusion Criteria:

  1. Participants who have or have a history of hepatobiliary diseases (e.g., severe hepatic impairment or viral hepatitis), renal diseases (e.g., severe renal impairment), neurological diseases, immune system disorders, respiratory diseases, gastrointestinal diseases, endocrine disorders, hematologic or neoplastic diseases, cardiovascular diseases (e.g., cardiac failure or Torsade de pointes), urinary system disorders, psychiatric disorders (e.g., mood disorder or obsessive-compulsive disorder), sexual dysfunction, or other relevant diseases
  2. Participants who have a history of gastrointestinal diseases (e.g., Crohn's disease, ulcer, gastritis, gastric spasm, or gastroesophageal reflux disease) or gastrointestinal surgery (except for simple appendectomy or hernia surgery) that may affect the evaluations of the safety, pharmacokinetics, and pharmacodynamics of the product
  3. Participants who have to P-CAB (Potassium-Competitive Acid Blocker), drugs of the same class, or any other drugs (e.g., Aspirin or other salicylates, antibiotics, or benzimidazole anthelmintics), or who have a history of clinically significant hypersensitivity
  4. Participants with hereditary problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
  5. Participants with positive serology results for , , (HIV), or syphilis
  6. Participants with a history of drug abuse or who test positive for drugs of abuse in a urine drug screening test
  7. Participants with any of the following vital sign values measured in the sitting position after at least 3 minutes of rest at screening:

    • Systolic blood pressure \< 80 mmHg or ≥ 140 mmHg
    • Diastolic blood pressure \< 45 mmHg or ≥ 90 mmHg
  8. Participants with > 450 msec or clinically significant abnormal rhythm findings on 12-lead at screening
  9. Participants with one or more of the following results in clinical laboratory tests conducted during screening, including additional tests:

    • (SGOT) or ALT (SGPT) > 1.5 x the
    • Estimated (eGFR, CKD-EPI equation) \< 90 mL/min/1.73m²
    • Blood count \< 130,000/μL, PT > 1.2, or aPTT > 36.4 sec
  10. Participants who have taken any prescription drug or herbal medicine within 2 weeks prior to the scheduled date of the first administration of the investigational product, or any OTC drug, health functional food including liver function supplements, or vitamin preparation within 1 week prior to the scheduled date of the first administration of the investigational product (however, participants may be enrolled if other conditions are deemed reasonable by the investigator), or who are expected to take any such product
  11. Participants who have taken drug-metabolizing enzyme-inducing drugs, such as barbiturates, or drug metabolism-inhibiting drugs, such as clarithromycin, within 1 month prior to the scheduled date of the first administration of the investigational product
  12. Participants who have participated in another clinical trial (including a bioequivalence trial) and received an investigational product within 6 months prior to the scheduled date of the first administration of the investigational product
  13. Participants who have donated whole blood within 2 months, or who have donated blood components or received a blood transfusion within 1 month prior to the scheduled date of the first administration of the investigational product.
  14. Participants (however, participants who stopped smoking at least 3 months prior to the scheduled date of the first administration of the investigational product may be enrolled), or heavy smokers (10 cigarettes/day), or participants who are unable to abstain from smoking until the end of the clinical trial
  15. Participants who regularly consume alcohol (>21 units/week; 1 unit = 10 g of pure alcohol) or are unable to abstain from alcohol from 3 days prior to the scheduled date of the first administration of the investigational product until the end of the clinical trial
  16. Participants who have regularly consumed excessive caffeine (>5 units/day; 1 unit = 80 mg of caffeine) or are unable to refrain from consuming caffeine-containing foods or beverages (e.g., coffee, tea (including black tea and green tea), carbonated beverages, coffee beverages, coffee milk, tonic drinks, and energy drinks) from 3 days prior to the scheduled date of the first administration of the investigational product until the end of the clinical trial
  17. Participants who have consumed or are unable to refrain from consuming grapefruit, grapefruit juice, or grapefruit-containing foods from 3 days prior to the scheduled date of the first administration of the investigational product until the end of the clinical trial
  18. Participants who have unusual dietary habits (e.g., consumption of ≥1 L of grapefruit juice per day) or are unable to consume the standardized diet provided by the Clinical Trials Center during the inpatient period
  19. Participants who, or whose spouse or partner, are unable to use a method considered highly effective throughout the entire clinical trial and for at least 4 weeks after the last administration of the investigational product, and participants who do not agree not to donate sperm during that period

    [Contraceptive Methods Considered Highly Effective]

    • Intrauterine device, intrauterine hormone-releasing system
    • Bilateral tubal occlusion
    • Sexual abstinence, only when defined as refraining from heterosexual intercourse throughout the entire period of risk.
  20. Participants determined by the investigator to be unsuitable for participation in this clinical trial for reasons other than those listed above.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Aspirin-Tegoprazan Sequence

    Period 1 (Day 1-Day 5): Participants receive aspirin 100 mg Period 2 (Day 16-Day 20): Participants receive tegoprazan 50 mg Period 3 (Day 21-Day 25): Participants receive tegoprazan 50 mg and aspirin 100 mg

    Drug: Aspirin · Drug: Tegoprazan · Drug: Tegoprazan + Aspirin

Interventions

  • QD, for 5 days

    Also known as: Aspirin Protect Tab. 100 mg

  • QD, for 5 days

    Also known as: K-CAB Tab. 50 mg

  • DrugTegoprazan + Aspirin

    Drug pages: Tegoprazan · Aspirin

    QD, for 5 days

06

What researchers measure

Primary outcomes

  1. Cmax,ss of Aspirin

    PK parameter of Aspirin

    Time frame: Day 1-Day 5, Day 22-Day 25 up to 24 hours

  2. AUCtau,ss of Aspirin

    PK parameter of Aspirin

    Time frame: Day 1-Day 5, Day 22-Day 25 up to 24 hours

  3. Cmax,ss of Tegoprazan

    PK parameter of Tegoprazan

    Time frame: Day 16-Day 20, Day 22-Day 25 up to 24 hours

  4. AUCtau,ss of Tegoprazan

    PK parameter of Tegoprazan

    Time frame: Day 16-Day 20, Day 22-Day 25 up to 24 hours

  5. Inhibition of Platelet Aggregation (%)

    PD parameter of Aspirin

    Time frame: Predose on Day 1 and 24 hours after the Day 5 dose; and predose on Day 21 and 24 hours after the Day 25 dose

  6. Inhibition of Thromboxane B2 (%)

    PD parameter of Aspirin

    Time frame: Predose on Day 1 and 24 hours after the Day 5 dose; and predose on Day 21 and 24 hours after the Day 25 dose

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Jan 2027, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2026
First posted
Oct 1, 2026
StartEst.
Oct 14, 2026
Primary completionEst.
Jan 31, 2027
CompletionEst.
Apr 30, 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07853248
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Oct 14, 2026 (estimated)
Primary completion
Jan 31, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Heeju Ahn
Contact
heeju.ahn21@inno-n.com
+82 31-5176-4662
Yugyeong Park
Contact
yugyeong.park@inno-n.com
+82 31-5176-4661
SeungHwan Lee
principal investigator · Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aspirin · Tegoprazan

Start the discussion